Fulcrum Therapeutics (FULC) Payables (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Payables for 9 consecutive years, with $3.4 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Payables rose 95.6% year-over-year to $3.4 million; the TTM figure through Jun 2026 stood at $3.4 million (up 95.6% YoY), while the FY2025 annual figure was $1.6 million, up 36.77% from the prior year.
• Payables grew to $3.4 million in Q2 2026 per FULC's latest filing, from $2.4 million in the prior quarter.
• Across five years, Payables topped out at $6.0 million in Q1 2022 and bottomed at $1.2 million in Q4 2024.
• Historically, Payables has averaged $3.2 million across 5 years, with a median of $3.5 million in 2023.
• Annual changes were most pronounced in 2025 — Payables sank 60.93% — and 2026, when it soared 95.6%.
• Fulcrum Therapeutics' Payables stood at $3.6 million in 2022, then declined by 24.22% to $2.8 million in 2023, then sank by 57.78% to $1.2 million in 2024, then surged by 36.77% to $1.6 million in 2025, then soared by 115.14% to $3.4 million in 2026.
• Business Quant data shows FULC's Payables at $3.4 million in Q2 2026, $2.4 million in Q1 2026, and $1.6 million in Q4 2025.